Merck withdraws Vioxx; FDA issues public health advisory.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004335:Drug and Narcotic Control; D007783:Lactones / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib